Goodrx Holdings, Inc. (GDRX)
NASDAQ:GDRX
Want to see GDRX full AI Analyst Report?
GDRX Stock Chart & Stats
$2.27
-$0.12(-2.72%)
At close: 4:00 PM EST
$2.27
-$0.12(-2.72%)
Day’s Range― - ―
52-Week Range$1.77 - $5.81
Previous CloseN/A
Volume261.88K
Average Volume (3M)1.72M
Market Cap
$911.04M
Enterprise Value$1.21B
Total Cash (Recent Filing)$235.71M
Total Debt (Recent Filing)$541.35M
Price to Earnings (P/E)45.9
Beta0.88
Next Earnings
Aug 06, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding104,711,190
10 Day Avg. Volume1,305,674
30 Day Avg. Volume1,716,407
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)1.21
P/FCF Ratio5.87
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda6.98
Forecast
1Y Price Target
$3.60Price Target Upside58.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)0.31
Revenue Forecast (FY)$775.88M
Bulls Say, Bears Say
Bulls Say
Profitability & Cash GenerationGoodRx has meaningfully returned to positive earnings and solid cash generation with very strong gross margins. Durable free cash flow provides flexibility to invest in strategic initiatives, absorb PTR volatility, and reduce reliance on external financing over the next several quarters.
Pharma Direct MomentumRapid Pharma Direct expansion diversifies revenue away from legacy transactions and scales higher-value manufacturer programs. With 125+ self-pay programs and direct pharmacy contracts, this structural shift improves revenue durability and positions GoodRx to capture manufacturer-directed distribution over the medium term.
Much Lower LeverageA materially de-levered balance sheet reduces financial risk and increases strategic optionality. Low leverage supports continued investment in product expansion, potential M&A, and shields operations from macro stress, improving long-term resilience despite top-line headwinds.
Bears Say
Legacy PTR DeclineA persistent 24% YoY drop in core prescription transactions erodes the high-volume base that historically underpinned fees and advertising. Continued PTR contraction weakens network effects, depresses scale economics, and forces reliance on faster-growing but initially smaller revenue streams.
Stagnant Monthly Active ConsumersFlat user engagement limits prescription flow and constrains ad and subscription monetization. Without renewed MAC growth, revenue gains must come from higher spend per user or manufacturer deals, increasing execution risk and making growth more dependent on product-led or partner-driven initiatives.
Weak Overall Revenue TrendFlat-to-declining top-line despite margin recovery signals structural challenges in reinvigorating demand for legacy offerings. Sustained weak revenue amplifies pressure on margins and ROI of customer acquisition, requiring consistent Pharma Direct and subscription expansion to restore durable top-line growth.
GoodRx Holdings News
GDRX FAQ
What was Goodrx Holdings, Inc.’s price range in the past 12 months?
Goodrx Holdings, Inc. lowest stock price was $1.77 and its highest was $5.81 in the past 12 months.
What is Goodrx Holdings, Inc.’s market cap?
Goodrx Holdings, Inc.’s market cap is $911.04M.
When is Goodrx Holdings, Inc.’s upcoming earnings report date?
Goodrx Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 41 days.
How were Goodrx Holdings, Inc.’s earnings last quarter?
Goodrx Holdings, Inc. released its earnings results on May 06, 2026. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.072 by -$0.002.
Is Goodrx Holdings, Inc. overvalued?
According to Wall Street analysts Goodrx Holdings, Inc.’s price is currently Undervalued.
Does Goodrx Holdings, Inc. pay dividends?
Goodrx Holdings, Inc. does not currently pay dividends.
What is Goodrx Holdings, Inc.’s EPS estimate?
Goodrx Holdings, Inc.’s EPS estimate is 0.08.
How many shares outstanding does Goodrx Holdings, Inc. have?
Goodrx Holdings, Inc. has 104,711,190 shares outstanding.
What happened to Goodrx Holdings, Inc.’s price movement after its last earnings report?
Goodrx Holdings, Inc. reported an EPS of $0.07 in its last earnings report, missing expectations of $0.072. Following the earnings report the stock price went up 10.506%.
Which hedge fund is a major shareholder of Goodrx Holdings, Inc.?
Currently, no hedge funds are holding shares in GDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GoodRx Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.60 (58.59% Upside)
$3.60 (58.59% Upside)
Blogger Sentiment
Bullish
GDRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 287.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.56%
12-Months-Change
Fundamentals
Return on Equity
3.31%
Trailing 12-Months
Asset Growth
56.05%
Trailing 12-Months
Company Description
Goodrx Holdings, Inc.
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
GDRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced material near-term headwinds in the legacy prescription transactions business (PTR) — notably a 24% YoY decline in PTR revenue and persistent unit-economics pressure — against strong and accelerating growth in strategic areas (Pharma Direct up 82% YoY, subscriptions +16% YoY), improved operational scalability in e-commerce, and a raised full-year guidance. Management emphasized durable strategy execution, margin discipline (30% adjusted EBITDA margin in Q1), and momentum in Pharma Direct and condition-specific subscriptions. While legacy PTR trends and macro/regulatory uncertainty are notable risks, the company’s improved guidance, profitable quarter, and rapid Pharma Direct expansion weigh positively.View all GDRX earnings summariesGDRX Revenue Breakdown
73.41% Prescription transactions
12.58% Subscription
11.34% Pharma manufacturer solutions
2.67% Other
GDRX Stock 12 Month Forecast
Average Price Target
$3.60
▲(58.59% Upside)
Technical Analysis
Ownership Overview
11.77% Insiders
11.57% Mutual Funds
9.75% Other Institutional Investors
57.31% Public Companies and
Individual Investors